Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

biotech shutter

Biotech

News

Health Care

Movers

Trading Ideas

General

IMMP

Immutep&#39;s INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Immutep&#39;s Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Screenshot 2024-09-16 at 5.51.32 PM

Earnings

Equities

Eurozone

Commodities

Markets

BBLG

DRMA

NCNA

NWTN

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September

movers image

Pre-Market Outlook

EZPW

GPRK

IART

IOVA

NAMS

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Immutep Limited - American Depositary Shares

Immutep Ltd

Press Releases

Immutep Quarterly Activities Report Q1 FY25

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Patient Enrolment Completed for INSIGHT-003

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Quarterly Activities Report Q2 FY25

Anika Therapeutics

Annexon

aTyr Pharma

Benitec Biopharma

Cidara Therapeutics

Celcuity

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Gossamer Bio

Heron Therapeutics

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

ITeos Therapeutics

Neurogene

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Regenxbio

Rezolute

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Verastem

XOMA Royalty

Baird

Capital One

Maxim Group

Comments

Immutep

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga